[ad_1]
ValuEngine upgraded shares of Mediwound (NASDAQ:MDWD) from a hold rating to a buy rating in a report published on Tuesday, October 2nd.
MDWD has been the topic of several other reports. Wells Fargo & Co set a $11.00 price target on Mediwound and gave the stock a buy rating in a research report on Tuesday, September 25th. Oppenheimer set a $14.00 price objective on Mediwound and gave the stock a buy rating in a report on Monday, September 24th. Finally, Zacks Investment Research cut Mediwound from a hold rating to a sell rating in a report on Wednesday, July 11th. One equities research badyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $11.33.
Shares of MDWD traded up $0.06 during trading hours on Tuesday, hitting $5.77. 17,098 shares of the company were exchanged, compared to its average volume of 35,144. Mediwound has a 52 week low of $3.56 and a 52 week high of $7.35.
Mediwound (NASDAQ:MDWD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.05. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. The business had revenue of $1.03 million during the quarter, compared to badysts’ expectations of $0.96 million. On average, equities research badysts forecast that Mediwound will post -0.71 earnings per share for the current year.
Several hedge funds have recently modified their holdings of MDWD. Nexthera Capital LP acquired a new position in Mediwound during the second quarter valued at $308,000. Wells Fargo & Company MN boosted its stake in shares of Mediwound by 19.9% during the 1st quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock worth $631,000 after acquiring an additional 20,134 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Mediwound by 10.4% during the 2nd quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock worth $900,000 after acquiring an additional 12,300 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Mediwound by 1.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock worth $14,478,000 after acquiring an additional 21,559 shares in the last quarter. Institutional investors and hedge funds own 32.58% of the company’s stock.
About Mediwound
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: How to Invest in Growth Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mediwound Daily – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings for Mediwound and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
